Clinical Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudin, C. M.
Right arrow Articles by Ratain, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudin, C. M.
Right arrow Articles by Ratain, M. J.
Clinical Cancer Research Vol. 7, 1214-1220, May 2001
© 2001 American Association for Cancer Research

Clinical Trials

Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer1

Charles M. Rudin2, Jon Holmlund, Gini F. Fleming, Sridhar Mani, Walter M. Stadler, Philip Schumm, Brett P. Monia, Joseph F. Johnston, Richard Geary, Rosie Z. Yu, T. Jesse Kwoh, F. Andrew Dorr and Mark J. Ratain

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois 60637-1470 [C. M. R., G. F. F., S. M., W. M. S., P. S., M. J. R.], and ISIS Pharmaceuticals, Inc., Carlsbad, California 92008 [J. H., B. P. M., J. F. J., R. G., R. Z. Y., T. J. K., F. A. D.]

Raf-1 is a serine/threonine kinase that functions as a critical effector of Ras-mediated signal transduction via the mitogen-activated protein kinase pathway. Constitutive activation of this pathway directly contributes to malignant transformation in many human tumors. A 20-base phosphorothioate oligonucleotide complementary to c-raf-1 mRNA (ISIS 5132; CGP 69846A) has been shown to specifically suppress Raf-1 expression both in vitro and in vivo. This Phase I trial, involving 22 patients with advanced cancer, was designed to evaluate the safety, feasibility, and maximum tolerated dose of ISIS 5132 administration as a weekly 24-h i.v. infusion. Pharmacokinetic analysis was performed, and c-raf-1 mRNA levels in peripheral blood mononuclear cells were assessed using quantitative reverse transcription-PCR. This trial defined a maximum tolerated dose of 24 mg/kg/week on this schedule. Two of four patients treated at 30 mg/kg/week had serious adverse events after the first dose of ISIS 5132, including acute hemolytic anemia and acute renal failure and anasarca. There were no major responses documented. Dose-dependent complement activation was demonstrated on this schedule, but not on previously evaluated schedules, of ISIS 5132 administration. In contrast to other trials of ISIS 5132, there appeared to be no consistent suppression of peripheral blood mononuclear cell c-raf-1 mRNA level on this schedule at any of the dose levels analyzed. These data suggest that the efficacy and toxicity profiles of antisense oligonucleotides may be highly dependent on the schedule of administration and support the analysis of the putative molecular target in the evaluation of novel therapeutics.




This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
F. Farassati, W. Pan, F. Yamoutpour, S. Henke, M. Piedra, S. Frahm, S. Al-Tawil, W. I. Mangrum, L. F. Parada, S. D. Rabkin, et al.
Ras Signaling Influences Permissiveness of Malignant Peripheral Nerve Sheath Tumor Cells to Oncolytic Herpes
Am. J. Pathol., December 1, 2008; 173(6): 1861 - 1872.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Kinkade, P. Dasgupta, A. Carie, D. Pernazza, M. Carless, S. Pillai, N. Lawrence, S. M. Sebti, and S. Chellappan
A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice
Cancer Res., May 15, 2008; 68(10): 3810 - 3818.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Liu, J. Kolesar, D. G. McNeel, C. Leith, K. Schell, J. Eickhoff, F. Lee, A. Traynor, R. Marnocha, D. Alberti, et al.
A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Clin. Cancer Res., May 1, 2008; 14(9): 2732 - 2739.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
B. S. Winters, B. K. M. Raj, E. E. Robinson, R. A. Foty, and S. A. Corbett
Three-dimensional Culture Regulates Raf-1 Expression to Modulate Fibronectin Matrix Assembly
Mol. Biol. Cell, August 1, 2006; 17(8): 3386 - 3396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Dritschilo, C. H. Huang, C. M. Rudin, J. Marshall, B. Collins, J. L. Dul, C. Zhang, D. Kumar, P. C. Gokhale, A. Ahmad, et al.
Phase I Study of Liposome-Encapsulated c-raf Antisense Oligodeoxyribonucleotide Infusion in Combination with Radiation Therapy in Patients with Advanced Malignancies
Clin. Cancer Res., February 15, 2006; 12(4): 1251 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Beeram, A. Patnaik, and E. K. Rowinsky
Raf: A Strategic Target for Therapeutic Development Against Cancer
J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Lowenberg, A. Verhaar, B. van den Blink, F. ten Kate, S. van Deventer, M. Peppelenbosch, and D. Hommes
Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn's Disease
J. Immunol., August 15, 2005; 175(4): 2293 - 2300.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. A. Desai, R. L. Schilsky, A. Young, L. Janisch, W. M. Stadler, N. J. Vogelzang, S. Cadden, J. A. Wright, and M. J. Ratain
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
Ann. Onc., June 1, 2005; 16(6): 958 - 965.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. S. Sridhar, D. Hedley, and L. L. Siu
Raf kinase as a target for anticancer therapeutics
Mol. Cancer Ther., April 1, 2005; 4(4): 677 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Rudin, J. L. Marshall, C. H. Huang, H. L. Kindler, C. Zhang, D. Kumar, P. C. Gokhale, J. Steinberg, S. Wanaski, U. N. Kasid, et al.
Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study
Clin. Cancer Res., November 1, 2004; 10(21): 7244 - 7251.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Cohen, E. Rosenbaum, S. Begum, D. Goldenberg, C. Esche, O. Lavie, D. Sidransky, and W. H. Westra
Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites
Clin. Cancer Res., May 15, 2004; 10(10): 3444 - 3447.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
J. B. Opalinska and A. M. Gewirtz
Therapeutic Potential of Antisense Nucleic Acid Molecules
Sci. Signal., October 28, 2003; 2003(206): pe47 - pe47.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Goel, K. Desai, A. Bulgaru, A. Fields, G. Goldberg, S. Agrawal, R. Martin, M. Grindel, and S. Mani
A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit {alpha} of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors
Clin. Cancer Res., September 15, 2003; 9(11): 4069 - 4076.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. C. Gokhale, C. Zhang, J. T. Newsome, J. Pei, I. Ahmad, A. Rahman, A. Dritschilo, and U. N. Kasid
Pharmacokinetics, Toxicity, and Efficacy of Ends-modified raf Antisense Oligodeoxyribonucleotide Encapsulated in a Novel Cationic Liposome
Clin. Cancer Res., November 1, 2002; 8(11): 3611 - 3621.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Dy and A. A. Adjei
Novel Targets for Lung Cancer Therapy: Part I
J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
P. d. Diesbach, F. N'Kuli, C. Berens, E. Sonveaux, M. Monsigny, A.-C. Roche, and P. J. Courtoy
Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking
Nucleic Acids Res., April 1, 2002; 30(7): 1512 - 1521.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
Ann. Onc., April 1, 2002; 13(4): 539 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Morris, W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al.
Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 679 - 683.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.